에 대한 최신 뉴스 Teladoc Health (NYSE:TDOC) 주식

Teladoc Health

Teladoc Health is a virtual health provider with a telehealth platform delivering on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has partnered with employers, health plans, and health systems to offer network access to their members; it has also started to market directly to consumers while expanding its service portfolio.

Earnings

News

Guidance

Health Care

After-Hours Center

Movers

TDOC

텔레닥 헬스(NYSE:TDOC)의 주가는 회사가 분석가 기대치를 뛰어넘는 3분기 재무 결과를 보고한 후 수요일 시간외 거래에서 11% 이상 급등했다.

텔레닥 헬스의 주식은 예상을 넘는 3분기 실적에 시간외 거래에서 11% 이상 급등

Equities

Markets

$BTC

$ETH

ARKF

ARKK

ARKW

COIN

PINS

수요일에 캐시 우드가 주도하는 아크 인베스트(Ark Invest)는 어드밴스드 마이크로 디바이시스(NASDAQ:AMD), 핀터레스트(NYSE:PINS), 코인베이스 글로벌(NASDAQ:

아크 인베스트가 AMD 주식을 $47.5백만 그리고 핀터레스트 주식을 $12.7백만 매수

Small Cap

Trading Ideas

원격 의료 회사인 텔레닥 헬스(NYSE:TDOC)는 수요일 시장 마감 후 2분기 재무 결과를 발표했다. 주요 하이라이트는 다음과 같다.

텔라닥 헬스:  엇갈린 2분기 실적과 연간 전망 지침 철회로 주가는급락, 52주 최저치 돌파

Teladoc Health Inc

Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $11.0, a high estimate of $14.00, and a low estimate of $8.00. This current average reflects an increase of 18.41% from the previous average price target of $9.29. 
<img src="https://www.benzinga.com/files/images/story/2024/1733320944_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of Teladoc Health's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$13.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$14.00</td>
<td>-</td>
</tr>
<tr>
<td>George Hill</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$12.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Steve Valiquette</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$12.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Charles Rhyee</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$8.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$10.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$9.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Glen Santangelo</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$10.00</td>
<td>$8.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Teladoc Health. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Teladoc Health compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Teladoc Health's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Teladoc Health's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/TDOC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Teladoc Health analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Teladoc Health</h2>
Teladoc Health is a virtual health provider with a telehealth platform delivering on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has partnered with employers, health plans, and health systems to offer network access to their members; it has also started to market directly to consumers while expanding its service portfolio.
<h3>Teladoc Health: A Financial Overview</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Teladoc Health's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -2.99%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Teladoc Health's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -5.2% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -2.21%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Teladoc Health's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.94% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Teladoc Health's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.05.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Unveiling 8 Analyst Insights On Teladoc Health

Piper Sandler analyst Jessica Tassan reiterates Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Overweight and raises the price target from $11 to $13.

Price Target

Reiteration

Piper Sandler Reiterates Overweight on Teladoc Health, Raises Price Target to $13

Teladoc Health's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) short percent of float has fallen 4.62% since its last report. The company recently reported that it has 25.69 million shares sold short, which is 19.39% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.79 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Teladoc Health Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732905912_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Teladoc Health has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Teladoc Health's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Teladoc Health's peer group average for short interest as a percentage of float is 5.33%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Teladoc Health?

Teladoc Health Launches New AI-Capabilities To Enhance Virtual Sitter Solution To Improve Patient Safety

Goldman Sachs analyst David Roman initiates coverage on Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Buy rating and announces Price Target of $14.

Initiation

Goldman Sachs Initiates Coverage On Teladoc Health with Buy Rating, Announces Price Target of $14

Deutsche Bank analyst George Hill maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Hold and raises the price target from $10 to $12.

Deutsche Bank Maintains Hold on Teladoc Health, Raises Price Target to $12

Barclays analyst Steve Valiquette maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Overweight and raises the price target from $10 to $12.

Barclays Maintains Overweight on Teladoc Health, Raises Price Target to $12

TD Cowen analyst Charles Rhyee maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Hold and lowers the price target from $9 to $8.

TD Cowen Maintains Hold on Teladoc Health, Lowers Price Target to $8

WIIM

Teladoc Health shares are trading higher after the company reported Q3 earnings and sales that beat analyst estimates.

Teladoc Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) shares are moving higher in extended trading Wednesday after the company reported financial results for the third quarter that <a href="https://www.benzinga.com/pressreleases/24/10/g41635843/teladoc-health-reports-third-quarter-2024-results">topped analyst expectations</a>.
<ul>
<li>Q3 Revenue: $640.51 million, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $631.16 million</li>
</ul>
<ul>
<li>Q3 EPS: Loss of 19 cents, versus estimates for a loss of 27 cents</li>
</ul>
Total revenue was down 3% on a year-over-year basis. Integrated Care segment revenue was up 2% year-over-year, while BetterHelp segment revenue declined 10% year-over-year. U.S. revenue fell 6% year-over-year, while International revenue grew 15%.
Cash flow from operations totaled $110.2 million in the third quarter. The company said it generated $79 million in free cash flow during the quarter.
&#8220;As we close out 2024, we are moving with urgency and making changes to more effectively leverage our leadership position in the complex and dynamic markets we serve. There is more work ahead of us, and 2025 will be an important repositioning year. Our focus remains on delivering consistent performance and driving long-term shareholder value,&#8221; said Chuck Divita, CEO of Teladoc Health.
Guidance: Teladoc expects fourth-quarter Integrated Care segment revenue to be flat to up 2.5% in the fourth quarter. The company expects full-year Integrated Care segment revenue to grow in the low single digits to mid-single digits.
TDOC Price Action: <a href="https://www.benzinga.com/quote/TDOC" target="_blank" rel="noreferrer noopener">Teladoc shares</a> were up 9.26 % in after-hours, trading at $9.68 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next: • <a href="https://www.benzinga.com/news/earnings/24/10/41637326/meta-platforms-q3-earnings-revenue-beat-eps-beat-daily-actives-up-5-strong-momentum-in-ai">Meta Platforms Q3 Earnings: Revenue Beat, EPS Beat, Daily Actives Up 5%, &#8216;Strong Momentum&#8217; In AI</a>
Photo: Courtesy of Teladoc.

Teladoc Health Q3 Earnings: Revenue Beat, EPS Beat, Shares Jump 10%

Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.27) by 29.63 percent. The company reported quarterly sales of $640.508 million which beat the analyst consensus estimate of $631.160 million by 1.48 percent. This is a 2.99 percent decrease over sales of $660.238 million the same period last year.

Earnings Beats

Teladoc Health Q3 2024 GAAP EPS $(0.19) Beats $(0.27) Estimate, Sales $640.508M Beat $631.160M Estimate

Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) is set to give its latest quarterly earnings report on Wednesday, 2024-10-30. Here's what investors need to know before the announcement.
Analysts estimate that Teladoc Health will report an earnings per share (EPS) of $-0.27. 
Investors in Teladoc Health are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings History Snapshot</h3>
The company's EPS beat by $0.06 in the last quarter, leading to a 8.91% drop in the share price on the following day.
Here's a look at Teladoc Health's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.34</td>
<td>-0.46</td>
<td>-0.21</td>
<td>-0.37</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.28</td>
<td>-0.49</td>
<td>-0.17</td>
<td>-0.35</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-9.0%</td>
<td>-2.0%</td>
<td>-24.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730224943_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Teladoc Health were trading at $9.18 as of October 28. Over the last 52-week period, shares are down 46.1%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<h3>Analyst Observations about Teladoc Health</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Teladoc Health.
The consensus rating for Teladoc Health is Neutral, based on 15 analyst ratings. With an average one-year price target of $10.47, there's a potential 14.05% upside.
<h3>Comparing Ratings with Peers</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Certara, Schrodinger and Phreesia, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Certara is maintaining an Neutral status according to analysts, with an average 1-year price target of $16.0, indicating a potential 74.29% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Schrodinger, with an average 1-year price target of $27.5, suggesting a potential 199.56% upside.</li>
<li>For Phreesia, analysts project an Buy trajectory, with an average 1-year price target of $29.4, indicating a potential 220.26% upside.</li>
</ul>
<h3>Overview of Peer Analysis</h3>
The peer analysis summary outlines pivotal metrics for Certara, Schrodinger and Phreesia, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Teladoc Health</td>
<td>Neutral</td>
<td>-1.53%</td>
<td>$454.38M</td>
<td>-44.19%</td>
</tr>
<tr>
<td>Certara</td>
<td>Neutral</td>
<td>3.17%</td>
<td>$53.50M</td>
<td>-1.20%</td>
</tr>
<tr>
<td>Schrodinger</td>
<td>Neutral</td>
<td>34.51%</td>
<td>$31.34M</td>
<td>-10.94%</td>
</tr>
<tr>
<td>Phreesia</td>
<td>Buy</td>
<td>18.97%</td>
<td>$69.30M</td>
<td>-7.15%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Teladoc Health ranks at the bottom for Revenue Growth and Gross Profit, while it is in the middle for Return on Equity. The company's performance is below average compared to its peers in terms of Revenue Growth and Gross Profit, but it is relatively better in terms of Return on Equity.
<h3>Get to Know Teladoc Health Better</h3>
Teladoc Health is a virtual health provider with a telehealth platform delivering on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has partnered with employers, health plans, and health systems to offer network access to their members; it has also started to market directly to consumers while expanding its service portfolio.
<h3>Financial Insights: Teladoc Health</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Teladoc Health's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately -1.53% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -130.39%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Teladoc Health's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -44.19%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Teladoc Health's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -21.36%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a high debt-to-equity ratio of 1.06, Teladoc Health faces challenges in effectively managing its debt levels, indicating potential financial strain.
<a href="https://www.benzinga.com/quote/TDOC/earnings">To track all earnings releases for Teladoc Health visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Preview Of Teladoc Health's Earnings

The healthcare technology sector is undergoing a transformation, with companies leveraging AI, telemedicine, and digital platforms to innovate the way care is delivered. As demand for more efficient and patient-centric solutions grows, several public companies have emerged as leaders in this space.&nbsp;
<h3>1. Teladoc Health</h3>
Market Cap: $1.4 Billion
Focus Area: Telehealth&nbsp;
Teladoc Health (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tdoc#NYSE">TDOC</a>) is a household name in telemedicine and virtual care, offering services in over 175 countries. As one of the pioneers of telehealth, Teladoc has continuously innovated its sm&nbsp; &nbsp; ervices, making healthcare more accessible and convenient. Its acquisition of Livongo, a leader in managing chronic conditions through AI and digital tools, has expanded its capabilities to cover a wide range of health conditions, from diabetes to hypertension.
What Teladoc does best is delivering a seamless virtual care experience across multiple specialties. The company also excels at integrating behavioral health services, allowing patients to receive both physical and mental healthcare from the comfort of their homes. Teladoc&rsquo;s robust data analytics and AI capabilities offer personalized treatment plans, making it one of the most comprehensive telehealth platforms available. With the global demand for virtual healthcare services on the rise, Teladoc&rsquo;s long-term growth prospects are strong.
<h3>2. WELL Health Technologies</h3>
Market Cap: $1.1 Billion
Focus Area: Digital Health Solutions&nbsp;
WELL Health Technologies (TSX: WELL) has become a key player in North America&#39;s digital healthcare market. Known for its extensive acquisition strategy, WELL has rapidly expanded its network of clinics and digital healthcare platforms. What sets WELL apart is its ability to integrate physical and virtual care through telemedicine, while also providing digital health solutions to clinics across Canada and the U.S.&nbsp;
WELL&#39;s partnership with Healwell AI is one of its most recent innovations, using AI to enhance clinical workflows, improve diagnosis accuracy, and optimize patient outcomes. This integration of AI into routine care is positioning WELL as a leader in AI-driven healthcare. Its platform also powers Wisp, a digital health solution that focuses on sexual and reproductive health, catering to underserved demographics, which further diversifies WELL&#39;s service offerings. As digital healthcare adoption increases, WELL&rsquo;s growth trajectory looks promising.
<h3>3. Omnicell</h3>
Market Cap: $1.9 Billion
Focus Area: Automation and analytics
Omnicell (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/omcl#NASDAQ">OMCL</a>) is a leader in automated medication management solutions, offering a range of products that streamline pharmacy operations and enhance medication adherence. Its offerings include advanced robotics, software solutions, and AI-powered analytics aimed at improving the accuracy and efficiency of drug dispensing in hospitals and clinics.
What Omnicell excels at is its ability to integrate automation with real-time data analytics. The company&rsquo;s solutions help healthcare providers reduce medication errors, optimize inventory management, and ensure regulatory compliance, ultimately improving patient safety. Omnicell&rsquo;s recent shift toward cloud-based, subscription-driven software services is expected to fuel recurring revenue growth, making it an attractive long-term investment. With automation playing a critical role in the future of healthcare, Omnicell is well-positioned to thrive.
<h3>4. IRadimed Corporation&nbsp;</h3>
Market Cap: $700 Million
Focus Area: MRI-Compatible Devices
IRadimed (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/irmd#NASDAQ">IRMD</a>) is pioneering in the MRI-compatible medical device space, addressing the safety challenges posed by traditional equipment in MRI environments. Their MRI-compatible infusion pumps and patient monitoring systems are designed to function safely without causing electromagnetic interference. This focus on MRI-specific safety is a niche yet crucial aspect of patient care, as it allows for uninterrupted and safer patient management during MRI procedures.
With increased utilization of MRI procedures in diagnostics, IRadimed&rsquo;s specialized products are seeing growing demand. The company is expanding its product lineup and entering new geographic markets, which positions it for sustained growth. IRadimed&rsquo;s focus on high-margin, niche products gives it a competitive advantage, contributing to steady revenue growth and profitability.
<h3>5. Evolent Health Inc.</h3>
Market Cap: $1.3 Billion
Focus Area: Value-Based Care
Evolent Health (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/evh#NYSE">EVH</a>) specializes in helping healthcare providers transition to value-based care models, which prioritize patient outcomes over service volume. By offering integrated clinical and administrative services, Evolent enables providers to focus on patient care while optimizing operational efficiencies. Their unique approach is centered on a data-driven platform called Identifi, which uses predictive analytics to guide care decisions and minimize costly interventions.
With the shift in the U.S. healthcare system towards value-based models, Evolent has positioned itself as a leader in this space. As more healthcare systems adopt this model, Evolent&rsquo;s solutions are likely to be in high demand. The company has been expanding through strategic partnerships and acquisitions, projecting steady revenue growth in the coming years.
<h3>6. CareDx, Inc.</h3>
Market Cap: $520 Million
Focus Area: Transplant Diagnostics
CareDx (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cdna#NASDAQ">CDNA</a>) specializes in providing precision diagnostics for transplant patients, focusing on improving graft survival rates. Their flagship product, AlloSure, is a non-invasive blood test that monitors donor-derived cell-free DNA, enabling early detection of organ rejection. By leveraging genomics and data analytics, CareDx offers a personalized approach that minimizes the need for biopsies and improves patient outcomes.
CareDx is positioned for growth as demand for non-invasive diagnostic solutions rises, particularly in the transplant community. The company is continually enhancing its testing solutions and expanding its presence in international markets. Although competition is intensifying, CareDx&rsquo;s innovative pipeline and established reputation should support long-term growth.
<h3>7. Tactile Systems Technology, Inc.</h3>
Market Cap: $450 Million
Focus Area: Chronic Disease Management
Tactile Medical (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcmd#NASDAQ">TCMD</a>) is addressing the problem of lymphedema and chronic swelling conditions, which often go underdiagnosed and undertreated. Their flagship product, the Flexitouch System, is a pneumatic compression device designed for at-home use, giving patients a non-invasive option for managing their symptoms. The company&#39;s focus on patient education and therapy adherence further differentiates it from competitors.
Tactile Medical has a robust market opportunity, given the growing prevalence of chronic diseases and the increased emphasis on at-home healthcare solutions. Despite recent headwinds due to reimbursement challenges, the company is expanding its product portfolio and expects growth as new regulatory changes potentially improve reimbursement rates.
<h4>Conclusion:</h4>
the healthcare technology sector is experiencing significant transformation driven by advancements in AI, telemedicine, and digital solutions. These innovations are reshaping how care is delivered, making it more efficient and patient-centric. As the demand for enhanced healthcare experiences grows, the industry is poised to improve outcomes and accessibility. Looking toward 2025, the ongoing evolution in this field will be critical in addressing the challenges facing healthcare systems worldwide.
This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.

CDNA

IRMD

OMCL

TCMD

Future Forward: 7 Groundbreaking Healthcare Technology Companies Poised To Disrupt the Industry By 2025

RBC Capital analyst Sean Dodge maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Outperform and raises the price target from $9 to $10.

RBC Capital Maintains Outperform on Teladoc Health, Raises Price Target to $10

Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) has been analyzed by 14 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $10.5, a high estimate of $17.00, and a low estimate of $8.00. Experiencing a 34.38% decline, the current average is now lower than the previous average price target of $16.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1728410417_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A clear picture of Teladoc Health's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$9.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Glen Santangelo</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$10.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$9.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$10.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>George Hill</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$10.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$10.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Charles Rhyee</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$9.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$9.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Steve Valiquette</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$10.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>David Grossman</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$9.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$8.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$17.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$17.00</td>
<td>$21.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Teladoc Health. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Teladoc Health compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Teladoc Health's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Teladoc Health's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/TDOC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Teladoc Health analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Teladoc Health: A Closer Look</h2>
Teladoc Health is a virtual health provider with a telehealth platform delivering on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has partnered with employers, health plans, and health systems to offer network access to their members; it has also started to market directly to consumers while expanding its service portfolio.
<h3>Teladoc Health: Financial Performance Dissected</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Teladoc Health's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately -1.53%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Teladoc Health's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -130.39%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -44.19%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -21.36%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.06, caution is advised due to increased financial risk.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Peeling Back The Layers: Exploring Teladoc Health Through Analyst Insights

Evercore ISI Group analyst Elizabeth Anderson maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a In-Line and raises the price target from $8 to $9.

Evercore ISI Group Maintains In-Line on Teladoc Health, Raises Price Target to $9

<a href="https://www.statnews.com/2024/09/23/addiction-treatment-telehealth-medication-opioid-use-disorder-dea-controlled-substances/#:~:text=A%20new%20bill%20being%20drafted,during%20the%20Covid%2D19%20pandemic.">https://www.statnews.com/2024/09/23/addiction-treatment-telehealth-medication-opioid-use-disorder-dea-controlled-substances/#:~:text=A%20new%20bill%20being%20drafted,during%20the%20Covid%2D19%20pandemic.</a>
Two Democratic lawmakers are working to preserve health providers' right to prescribe controlled substances via telehealth, including stimulants for ADHD and buprenorphine for opioid addiction.&nbsp;
A new bill being drafted by Sen. Mark Warner (D-Va.) and Rep. Doris Matsui (D-Calif.) comes months before the expiration of temporary waivers first enacted by the Drug Enforcement Administration's during the Covid-19 pandemic. Though the DEA is currently contemplating new regulations that would roll back many of the pandemic-era flexibilities, the lawmakers' new bill would likely extend the current rules through 2026, according to two lobbyists familiar with the effort.&nbsp;&nbsp;
The flexible rules are set to expire at the end of the year, which telehealth advocates say could threaten patient access to medications, including stimulants for ADHD and common medications used to treat opioid addiction.&nbsp;

Biotech

General

'Lawmakers Push To Let Telehealth Providers Keep Prescribing Stimulants And Addiction Treatment; Flexibility Allowed During Pandemic Is Set To Expire At Year-End' - STAT News

Analysts' ratings for Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) over the last quarter vary from bullish to bearish, as provided by 14 analysts.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $10.57, a high estimate of $17.00, and a low estimate of $8.00. Observing a downward trend, the current average is 35.67% lower than the prior average price target of $16.43. 
<img src="https://www.benzinga.com/files/images/story/2024/1726603234_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive Teladoc Health is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glen Santangelo</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$10.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$9.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$10.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>George Hill</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$10.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$10.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Charles Rhyee</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$9.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$9.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Steve Valiquette</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$10.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>David Grossman</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$9.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$8.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$17.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$17.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$10.00</td>
<td>$14.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Teladoc Health. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Teladoc Health compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Teladoc Health's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Teladoc Health's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TDOC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Teladoc Health analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Teladoc Health</h2>
Teladoc Health is a virtual health provider with a telehealth platform delivering on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has partnered with employers, health plans, and health systems to offer network access to their members; it has also started to market directly to consumers while expanding its service portfolio.
<h3>Breaking Down Teladoc Health's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Decline in Revenue: Over the 3 months period, Teladoc Health faced challenges, resulting in a decline of approximately -1.53% in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Teladoc Health's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -130.39%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Teladoc Health's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -44.19%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Teladoc Health's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -21.36%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Teladoc Health's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.06, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Evaluating Teladoc Health: Insights From 14 Financial Analysts

Teladoc Health shares are trading higher after Jefferies raised its price target on the stock from $8 to $10.

Jefferies analyst Glen Santangelo maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Hold and raises the price target from $8 to $10.

Jefferies Maintains Hold on Teladoc Health, Raises Price Target to $10

Teladoc (TDOC) Health announced the launch of new AI-enabled capabilities to enhance its Virtual Sitter solution to improve patient safety, address...

Teladoc launches new AI-enabled capabilities for Virtual Sitter solution

Bullish option flow detected in Teladoc (TDOC) with 19,909 calls trading, 3x expected, and implied vol increasing almost 4 points to 73.24%. 11/29 ...

Teladoc call volume above normal and directionally bullish

Teladoc: Maybe This Goose Isn't Cooked Yet (Rating Upgrade)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on BeiGene (BGNE – Research Report) and Teladoc (TDOC – Research Rep...

Analysts Offer Insights on Healthcare Companies: BeiGene (BGNE) and Teladoc (TDOC)

Teladoc: Why I'm Long This Inflection Stock

Teladoc Health, Inc. (TDOC) Piper Sandler 36th Annual Healthcare Conference (Transcript)

Piper Sandler raised the firm's price target on Teladoc (TDOC) to $13 from $11 and keeps an Overweight rating on the shares following a Fireside Ch...

Teladoc price target raised to $13 from $11 at Piper Sandler

Out-of-consensus buy ideas according to Goldman: CAG, TRIP, TDOC

In a report released today, Allen Lutz from Bank of America Securities maintained a Hold rating on Teladoc (TDOC – Research Report). The company's ...

Teladoc (TDOC) Receives a Hold from Bank of America Securities

Teladoc: Attractive Valuation, But The Narrative Stalls

AMGN

BGNE

BMBL

DINO

DLTR

ENPH

FBIN

INVH

MNST

MRNA

MYGN

OKTA

POOL

TREX

TRIP

WOLF

Press Releases

Harmonic Growth Partners Welcomes Daniel Vernic as Principal, Strengthening its Unique Investment Model of Experienced Investors and World-Class CEOs

Teladoc Health Announces Employee Inducement Award under NYSE Rule 303A.08

Teladoc Health Announces Employee Inducement Awards under NYSE Rule 303A.08

Teladoc Health to Announce Third Quarter 2024 Financial Results

Teladoc Health Reports Third Quarter 2024 Results

Teladoc Health Announces Employee Inducement Awards Under NYSE Rule 303A.08

Artificial Intelligence (AI) Reshaping Healthcare Industry with Unimaginable Potential

Teladoc Health to Participate in Upcoming Investor Conference

Teladoc Health Expands AI Capabilities for Hospitals and Health Systems with Advanced Virtual Sitter Solution

Opinion

AI Healthcare Innovations: How They're Shaping the Future for Patients and Investors

AVAI

BFLY

CLOV

HWAIF

PTON

RHHBY

TSX:AIDX

TSX:WELL

American Well Corporation Class A Common Stock

American Well

CareCloud

Certara

Definitive Healthcare Corp. - Class A Common Stock

Definitive Healthcare

Doximity

DarioHealth

Evolent Health

Forian

GoodRx Holdings, Inc. - Class A Common Stock

GoodRx Holdings

Health Catalyst

HealthStream

icad

LifeMD

MultiPlan Corporation Class A Common Stock

MultiPlan

OneMedNet

OptimizeRx

Phreesia

Pheton Holdings Ltd - Class A Ordinary Shares

Pheton Holdings

Scienture Holdings

Schrodinger

Simulations Plus

Sophia Genetics

TruBridge

Veeva Systems

Waystar Holding

Piper Sandler

Goldman Sachs

Deutsche Bank

Barclays

TD Cowen

텔레닥 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>)의 주가는 회사가 <a href="https://www.benzinga.com/pressreleases/24/10/g41635843/teladoc-health-reports-third-quarter-2024-results" target="_blank" rel="noopener" data-google-interstitial="false">분석가 기대치를 뛰어넘는</a> 3분기 재무 결과를 보고한 후 수요일 시간외 거래에서 11% 이상 급등했다.
<ul>
<li>3분기 매출: 6억 4,051만 달러, <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noopener" data-google-interstitial="false">예상치</a>인 6억 3,116만 달러를 상회</li>
</ul>
<ul>
<li>3분기 EPS: 19센트 손실, 예상 손실 27센트보다 개선됨</li>
</ul>
총 매출은 전년 대비 3% 감소했다. 통합 케어 부문 매출은 전년 대비 2% 증가했으며, 베터헬프(BetterHelp) 부문 매출은 10% 감소했다. 미국 매출은 전년 대비 6% 감소했지만, 국제 매출은 15% 증가했다.
3분기 영업 현금 흐름은 1억 1,020만 달러였으며, 이 회사는 분기 동안 7,900만 달러의 잉여 현금 흐름을 생성했다고 밝혔다.
&#8220;2024년을 마무리하면서 우리는 긴급하게 움직이고 있으며, 우리가 제공하는 복잡하고 역동적인 시장에서의 리더십 위치를 보다 효과적으로 활용하기 위해 변화를 만들고 있다. 우리는 앞으로 더 많은 작업이 있으며, 2025년은 중요한 재편성의 해가 될 것이다. 우리의 초점은 일관된 성과를 제공하고 장기적인 주주 가치를 증대시키는 것이다&#8221;라고 텔레닥 헬스의 CEO인 척 디비타(Chuck Divita)가 말했다.
가이던스: 텔레닥은 4분기 통합 케어 부문 매출이 전분기 대비 0%에서 2.5% 증가할 것으로 예상하고 있다. 연간 통합 케어 부문 매출은 저단위에서 중단위 성장할 것으로 예상하고 있다.
TDOC 주가 움직임: 텔레닥의 주식은 수요일 애프터 마켓에서 11.63% 상승하여 9.89달러에 거래되었다.
다음 읽어보기: 
• <a href="https://kr.benzinga.com/news/usa/stocks/%EB%A9%94%ED%83%80-3%EB%B6%84%EA%B8%B0-%EC%8B%A4%EC%A0%81-%EB%A7%A4%EC%B6%9C-%EB%B0%8F-eps-%EC%98%88%EC%83%81-%EC%83%81%ED%9A%8C-%EC%9D%BC%EC%9D%BC-%ED%99%9C%EC%84%B1-%EC%82%AC%EC%9A%A9%EC%9E%90-5/" target="_blank" rel="noopener">메타 플랫폼스 3분기 실적: 매출 및 EPS 예상치 상회, 일일 활성 사용자 5% 증가, AI 분야 강력한 모멘텀</a>
사진: Teladoc 제공.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

수요일에 캐시 우드가 주도하는 아크 인베스트(Ark Invest)는 어드밴스드 마이크로 디바이시스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), 핀터레스트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>), 코인베이스 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>)에서 상당한 거래를 했다. 아크는 파괴적인 혁신에 중점을 두는 것으로 유명하다.
AMD 거래
아크 인베스트는 ARK Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)와 ARK Next Generation Internet ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>)를 통해 AMD 주식 328,527주를 매입했다. 거래 금액은 4,746만 달러에 이른다. AMD 주가는 수요일 정규 세션을 4.4% 상승한 144.48달러에 마감했다.
이러한 움직임은 AMD의 2분기 실적 보고서가 예상을 뛰어넘고 회사 주가의 반등으로 이어진 이후에 나온 것이다. AMD의 분기별 수치는 주로 데이터 센터 매출의 강세와 클라이언트 비즈니스의 긍정적인 성과에 힘입어 <a href="https://www.benzinga.com/news/earnings/24/07/40051646/amd-shares-rebound-after-chipmaker-posts-q2-beat-guidance-tops-expectations-ceo-lisa-su-says-ai-bus" target="_blank" rel="noopener" data-google-interstitial="false">전년 대비 매출과 이익이 증가</a>한 것으로 나타났다.
AMD의 주가는 실적 보고서 이후 크게 급등하여 유명 투자자들이 이 칩 제조업체에 재투자하기로 한 <a href="https://www.benzinga.com/markets/equities/24/07/40057114/amds-results-proved-our-plan-to-reinvest-in-the-stock-was-right-says-jim-cramer-who-credits-lisa" target="_blank" rel="noopener" data-google-interstitial="false">결정을 입증</a>했다. 이번 성과에는 이 회사의 새로운 인공지능 칩인 MI300X가 중추적인 역할을 했다.
핀터레스트(PINS) 거래
아크 인베스트는 또한 Ark Fintech Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#NYSE">ARKF</a>), ARKK 및 ARKW ETF 전반에 걸쳐 핀터레스트 지분을 늘렸다. 총 매입 주식수는 398,257주이다. 핀터레스트 주식 구매 금액은 종가 31.95달러를 기준으로 약 1,272만 달러이다.
이 결정은 핀터레스트의 2분기 실적 보고서에 따른 것으로, 매출과 EPS 추정치를 웃돌았다. 그러나 핀터레스트의 3분기 <a href="https://www.benzinga.com/news/earnings/24/07/40051745/pinterest-q2-earnings-revenue-eps-beat-but-weak-guidance-weighs-on-shares" target="_blank" rel="noopener" data-google-interstitial="false">약한 지침</a>은 주가에 부담을 주었다. 그럼에도 불구하고 아크 인베스트의 움직임은 이 회사의 장기적인 전망에 대한 자신감을 시사한다.
특히 핀터레스트의 경쟁사인 마크 저커버그가 이끄는 메타 플랫폼스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)가 <a href="https://www.benzinga.com/news/earnings/24/07/40081701/meta-platforms-q2-earnings-revenue-beat-eps-beat-strong-guidance-meta-ai-is-on-track-to-be-the-most">강력한 2분기 실적</a>을 발표한 날 거래가 이루어졌다.
코인베이스(COIN) 거래
아크 인베스트는 ARKW ETF에서 코인베이스의 주식 12,077주를 매각했다. COIN 매도의 총 가치는 종가 224.36달러를 기준으로 약 270만 달러이다.
이번 매각은 비트코인과 이더리움 ETF 승인이 상위 2개 암호화폐인 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)과 이더리움(CRYPTO:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/eth-usd" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for ETH/USD">ETH</a>)에 대한 수요에 미치는 영향을 보여줄 것으로 예상되는 코인베이스의 2분기 실적 보고서에 앞서 이루어졌다.
이란 최고 지도자가 이스라엘에 대한 직접 공격을 명령한 후 비트코인은 66,500달러에서 64,000달러 초반 수준으로 하락하여 <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/40088529/bitcoin-ethereum-dogecoin-slip-amid-flare-up-of-iran-israel-tensions-analyst-says-a-big-mo" target="_blank" rel="noopener" data-google-interstitial="false">시장 정서에 극적인 변화</a>와 광범위한 청산을 일으켰다.
기타 주요 거래:
아크 인베스트는 ARKK ETF를 통해 줌 비디오 커뮤니케이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) 및 텔레닥 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>)의 주식을 매도했다.
아크 인베스트는 ARKG ETF를 통해 가든트 헬스(GH)와 인텔리아 테라퓨틱스(NTLA)의 주식을 매입했다. 아크 인베스트는 ARKW ETF에서 베라사이트(VCYT)의 주식을 매도했다.
다음 읽어보기: 
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ec%9d%b4%eb%9e%80%ec%9d%98-%ec%9d%b4%ec%8a%a4%eb%9d%bc%ec%97%98%ec%97%90-%eb%8c%80%ed%95%9c-%eb%b3%b4%eb%b3%b5-%eb%a7%b9%ec%84%b8%eb%a1%9c-%ec%9c%a0%ea%b0%80-2023%eb%85%84-10%ec%9b%94-%ec%9d%b4/" target="_blank" rel="noopener">이란의 이스라엘에 대한 보복 맹세로 유가 2023년 10월 이후 최대 일일 급등: UN, 긴급 회의 개최</a></li>
</ul>
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>를 통해 작성되었으며 <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>에 의해 편집되었습니다.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

원격 의료 회사인 텔레닥 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>)는 <a href="https://www.benzinga.com/earnings" target="_blank" rel="noopener" data-google-interstitial="false">수요일 시장 마감</a> 후 2분기 재무 결과를 발표했다.
주요 하이라이트는 다음과 같다.
어떤 일이 (What Happened): 텔레닥은 2분기 매출이 6억 4,240만 달러로 전년 대비 2% 감소했다고 보고했다. <a href="https://pro.benzinga.com/feature/newsfeed/?gspk=bHVrZWphY29iaTUzNDg&amp;gsxid=tdEE0VrK8Jeg&amp;ref=lukejacobi5348" target="_blank" rel="noopener">Benzinga Pro</a>의 데이터에 따르면 총 매출은 월가 합의 추정치인 6억 4,970만 달러를 밑돌았다.
이 회사는 2분기에 주당 28센트의 손실을 보고했는데, 이는 월가의 추정 주당 35센트 손실을 뛰어넘는 수치이다.
통합 케어 부문 매출은 3억 7,740만 달러로 해당 분기에 전년 대비 5% 증가했으며, 베터헬스(BetterHealth) 부문 매출은 2억 6,500만 달러로 분기에 전년 대비 9% 감소했다.
2분기 미국 매출은 5억 4,080만 달러로 전년 동기 대비 4% 감소했다. 2분기 해외 매출은 1억 160만 달러로 전년 동기 대비 12% 증가했다.
&#8220;텔레닥 헬스에 입사하게 되어 앞으로 회사를 이끌 기회를 얻게 되어 우리의 강점을 기반으로 더 높은 수준의 성과를 창출할 수 있게 되어 기쁘다. 우리의 확장된 위치, 핵심 역량, 재능 있는 직원들은 이러한 측면에서 우리를 잘 배치한다&#8221;고 텔레닥 핼스의 CEO인 척 디비타(Chuck Divita)가 말했다.
다음은: 이 회사는 통합 운영과 베터헬스 부문에 대한 연간 재무 전망을 철회한다고 밝혔다. 이 회사는 통합 운영에 대한 3년 전망도 철회했다.
디비타는 &#8220;통합 진료 부문에서 탄탄한 성과를 달성한 반면 베터헬스 부문에서 계속되는 역풍이 전반적인 결과에 영향을 미쳤다&#8221;고 말했다. &#8220;우리는 시간이 지남에 따라 회사 전체에서 더 큰 가치를 창출하기 위해 긴급하게 우리 앞에 놓인 작업을 해결하는 데 집중하고 있다.&#8221;
TDOC 주가 움직임: 수요일 애프터마켓에서 텔라닥의 주식은 14.35% 하락한 8.06달러에 거래되었다. 이는 52주 최저가인 8.73달러를 하회하는 수치이다.
사진: Ground Picture/Shutterstock.com
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

수요일에 캐시 우드가 이끄는 아크 인베스트(Ark Invest)는 이 회사의 인상적인 2분기 납품 실적에 힘입은 최근 상승세에도 불구하고 테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)의 상당 수의 주식을 매각하여 주목할만한 움직임을 보였다.
테슬라 주식
아크 인베스트는 ARK Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)를 통해 테슬라 지분을 줄여 13,213주를 매각했다. 이번 거래는 테슬라의 주가가 최근 화요일에 10.20% 급등해 4월 말 이후 최고의 장중 거래를 기록했다는 점을 감안하면 놀라운 일이었다. 특히 화요일에 아크 인베스트는 <a href="https://www.benzinga.com/markets/equities/24/07/39611275/cathie-woods-ark-invest-sells-tesla-shares-worth-14-5m-amid-rally-driven-by-q2-delivery-numbers-">1,450만 달러</a> 상당의 테슬라 주식을 매각했다.
이러한 상승은 주로 일론 머스크가 이끄는 이 회사의 <a href="https://www.benzinga.com/markets/equities/24/07/39595720/tesla-deliveries-fall-for-second-straight-quarter-but-stock-takes-off-as-q2-numbers-exceed-expec">2분기 실적</a>에 의해 주도되었다. 테슬라는 예상 차량 439,000대를 크게 초과하는 443,956대를 인도했다고 보고했다. 이러한 놀라운 상승세는 랠리를 촉진하여 주가를 2024년 최고치로 끌어올렸다. 판매의 대부분은 저렴한 모델 3 및 Y에서 이루어졌으며, 더 비싼 모델 X, S 및 신형 사이버트럭에서는 21,551대만 판매되었다.
최종 종가 246.39달러를 기준으로 수요일에 판매된 주식의 가치는 약 325만 달러에 달한다. 이날 테슬라 주가는 6.5% 급등했다.
기타 중요한 거래:
<ul>
<li>아크 인베스트의 ARKF 펀드는 텔레닥(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>)의 주식을 팔았다.</li>
<li>ARKG 펀드는 인텔리아 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>)의 주식을 2,551주 매수하고, 버브 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>)의 주를 팔았다.</li>
<li>ARKK 펀드는 아처 에비에이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NASDAQ">ACHR</a>)의 주를 사고, 깅코 바이오웍스 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNA#NYSE">DNA</a>)의 주를 팔았다.</li>
<li>ARKQ 펀드는 에어로바이런먼트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>)의 주를 팔았다. ARKX 펀드는 블레이드 에어 모빌리티(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLDE#NASDAQ">BLDE</a>)의 주를 샀다.</li>
</ul>
이미지는 셧터스톡을 통해 제공됨
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>를 사용하여 <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>이 편집했다

ETFs

ACHR

AVAV

BLDE

NTLA

TSLA

VERV

아크 인베스트가 예상을 넘는 2분기 배송 실적에도 $3.25백만 규모 테슬라 주식 매도 추가

월요일에 캐시 우드가 주도하는 아크 인베스트(Ark Invest)는 팔란티어 테크놀로지스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>)에 주목할 만한 투자를 했다. 이는 인공 지능(AI) 부문이 탄력을 받으면서 이루어진 움직임이다.
팔란티어(PLTR) 거래
아크 인베스트는 ARK Autonomous Technology &amp; Robotics ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKQ#BATS">ARKQ</a>)를 통해 팔란티어의 주식 199,372주를 매입했는데, 이는 포트폴리오에 상당한 추가 금액이다. 이번 거래 가치는 당일 종가 25.88달러를 기준으로 약 516만 달러에 이른다.
팔란티어는 최근 모멘텀 투자자들로부터 &#8216;AI 헤일로(AI Halo)&#8217; 플레이로 칭찬을 받았다. 이 회사는 3분기 BofA 증권의 미국 최고의 아이디어 10개 목록에 추가되어 AI 부문에서 점점 더 <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39582335/momentum-investor-praises-palantir-as-ai-halo-play-highlights-datadog-as-software-bottom">인기</a>를 얻고 있음을 강조했다. 버투스 인베스트먼트 파트너스(Virtus Investment Partners)의 조 테라노바(Joe Terranova)는 팔란티어가 AI 후광에 적극적으로 참여하는 AI 공간의 핵심 플레이어라고 설명했다.
팔란티어의 공동 창립자 피터 틸(Peter Thiel)은 최근 아스펜 아이디어 페스티벌(Aspen Ideas Festival)에서 AI 환경에 대한 <a href="https://www.benzinga.com/news/24/07/39569675/palantirs-peter-thiel-says-its-very-strange-that-most-money-in-ai-is-being-made-by-only-one-company" target="_blank" rel="noopener">통찰력</a>을 공유하면서 닷컴 버블과 AI의 현재 상태 사이의 유사점을 그렸다.
그 외의 중요한 거래:
<ul>
<li>아크 인베스트의 ARKG가 어댑티브 바이오 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>)의 주식을 매수했다.</li>
<li>ARKK는 리커전 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) 주식을 구매했다. ARKQ도 블레이드 에어 모빌리티(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLDE#NASDAQ">BLDE</a>)의 주식도 포트폴리오에 추가했다.</li>
<li>ARKF는 텔레닥 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>)의 주식을 팔았다.</li>
</ul>
이 이야기는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>를 통해 제공되었으며, <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>에 의해 편집되었다.

ADPT

ARKQ

PLTR

RXRX

캐시 우드의 아크 인베스트는 AI 열풍 속에서 516만 달러 가치의 팔란티어 주식 매수

수요일에 캐시 우드가 주도하는 아크 인베스트(Ark Invest)는 변동성이 큰 시장 속에서 로쿠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>)와 코인베이스 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>)에서 상당한 거래를 했다. 이러한 눈에 띄는 거래는 아크의 다양한 ETF가 수행한 일련의 거래의 일부였다.
로쿠 거래
ARK 혁신 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)와 ARK 차세대 인터넷 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>)는 로쿠에서 127,540주를 매입했다. ARKK 펀드는 106,420주를 인수했고, ARKW 펀드는 21,120주를 추가했다. 이 거래액은 730만 달러에 달했다. 수요일, 로쿠의 주가는 정기 세션에서 4.6% 상승한 57.16달러로 마감했다.
특히 우드의 회사는 <a href="https://www.benzinga.com/markets/equities/24/06/39493817/cathie-wood-led-ark-invest-dumps-4-3m-worth-of-nvidia-shares-amid-rebound-swoops-into-buy-stock-">하루 전</a>에 530만 달러 상당의 로쿠 주식을 구매했다. 이러한 움직임은 <a href="https://www.benzinga.com/general/entertainment/24/06/39422115/roku-stocks-wild-ride-bullish-analysts-bet-on-growth-despite-competitive-threats" target="_blank" rel="noopener">치열한 강세와 약세 논쟁</a> 사이에 주식이 갇힌 로쿠의 격동적인 시장 움직임 속에서 이루어졌다.
TV 스트리밍 플랫폼이자 넷플릭스와 같은 스트리밍 플랫폼의 경쟁사인 로쿠는 <a href="https://www.benzinga.com/markets/equities/24/06/39295418/whats-going-on-with-tv-streaming-platform-rokus-shares-on-wednesday">최근</a> 광고 인벤토리와 광고주 수요를 직접 연결하는 광고 기술 솔루션인 로쿠 익스체인지(Roku Exchange)를 출시했다.
코인베이스 거래
아크 인베스트의 ARKW ETF는 703,393달러 상당의 코인베이스 주식 3,278주를 매각했다. 이번 판매는 미국 정부와 연결되어 있는 것으로 여겨지는 지갑을 통해 상당한 규모의 암호화폐가 코인베이스로 <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39511595/uncle-sam-on-the-move-us-government-transfers-millions-in-bitcoin-to-coinbase" target="_blank" rel="noopener">이전</a>된 데 따른 것이다. 미국 정부는 2억 4,100만 달러 상당의 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) ​​3,940개를 코인베이스로 이전했다.
미국 정부의 이러한 움직임으로 인해 암호화폐 시장이 <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39516076/bitcoin-ethereum-dogecoin-retrace-on-fears-of-240m-sale-by-us-government-king-crypto-shoul">하락</a>했다. 비트코인은 이전 거래 세션에서 62,000달러로 약간 반등한 후 61,000달러 아래로 떨어졌다.
그 외 핵심 거래들:
<ul>
<li>아크 인베스트의 ARKG ETF는 깅코 바이오웍스 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNA#NYSE">DNA</a>)의 주식을 팔고 10X 지노믹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>)의 주식을 샀다.</li>
<li>ARKG 펀드는 텔레닥 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>)의 주식을 매도하고 인텔리아 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>)의 주식을 샀다.</li>
</ul>
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>가 작성하고 <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>이 편집한 바 있다.

Cryptocurrency

ROKU

아크 인베스트는 로쿠 $730만의 주식을 매수, 비트코인 하락에 코인베이스 주식을 매각

월요일에는 캐시 우드가 주도하는 아크 인베스트(Ark Invest)가 몇 가지 중요한 거래를 했으며, 그 가운데 코인베이스 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>)의 거래가 주목을 받았다. 이는 특히 암호화폐의 경우 격동적인 시장 시나리오 속에서 발생했다.
코인 거래
이날 아크 인베스트의 가장 눈에 띄는 거래는 대표적인 암호화폐 거래소 플랫폼인 코인베이스와의 거래였다. 이번 거래는 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) ​​가격이 62,000달러 아래로 떨어지는 등 <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39459091/coinbase-shares-tumble-with-bitcoin-whats-going-on-with-the-stock" target="_blank" rel="noopener" data-google-interstitial="false">암호화폐 시장이 상당한 변동성</a>을 겪고 있는 시기에 이루어졌다. 이러한 비트코인 ​​가격 하락은 코인베이스 주가에 직접적인 영향을 미쳤으며 월요일에도 하락세를 보였다.
코인베이스 주가는 월요일 정규 세션이 끝날 때 212.31달러를 기록했다. 이 회사는 ARK 차세대 인터넷 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>)를 통해 3,341개의 코인베이스 주식을 매도했다. 이 거래 금액은 709,327달러이다.
기타 중요한 거래:
<ul>
<li>텔레닥 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>): ARKG ETF에서 54,256주, ARKK ETF에서 61,606주를 매도했다.</li>
<li>앱사이이(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>): ARKG ETF를 통해 43,936주를 매수했다.</li>
<li>버브 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>): ARKG ETF에서 10,570주, ARKK ETF에서 50,971주를 매도했다.</li>
<li>로쿠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>): ARKK ETF를 통해 32,989주를 매수했다.</li>
</ul>
다음 읽기: <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39448829/bitcoin-ethereum-dogecoin-fall-on-investor-worries-analyst-warns-of-king-cryptos-dip-below?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">투자자 우려로 비트코인, 이더리움, 도지코인 가격 하락</a>
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>에서 제공한 내용을 바탕으로 <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>이 수정했습니다.

ABSI

아크 인베스트는 비트코인이 $62,000 아래로 하락하면서 코인베이스 주식을 매도

캐시 우드가 이끄는 아크 인베스트(Ark Invest)는 수요일에 로빈후드 마켓(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) 및 줌 비디오 커뮤니케이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>)괴 관련하여 상당한 거래를 했다.
로빈후드 주식의 거래
아크 인베스트는 Ark Fintech Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#NYSE">ARKF</a>)와 ARK Next Generation Internet ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>)를 통해 약 153만 달러 상당의 로빈후드 주식 64,706주를 매각했다. 이러한 움직임은 이 회사가 최근 시장 변동으로 인해 로빈후드의 <a href="https://www.benzinga.com/markets/equities/24/06/39263031/cathie-wood-lead-ark-invest-dumps-7-6m-worth-of-robinhood-shares-amid-gamestop-buzz-bitcoin-chop">보유 지분</a>을 줄인 후에 나온 것이다. 이 회사의 주가는 현재 5월 영업 데이터 발표 이후 상승하고 있다.
특히 로빈후드 거래는 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)과 이더리움(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)의 가격이 약간의 상승세를 보였지만 연방준비은행(연준)의 금리 인하에 대한 매파적인 지침으로 인해 <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39303902/bitcoin-ethereum-dogecoin-fail-to-sustain-uptrend-after-feds-hawkish-guidance-analyst-fore" target="_blank" rel="noopener" data-google-interstitial="false">이 랠리는 지속되지 않았다</a>.
줌 주식 거래
아크 인베스트는 ARKW를 통해 54,165주, 약 330만달러 상당의 줌 주식을 매도했다. 이 결정은 회사가 지난달 <a href="https://www.benzinga.com/news/earnings/24/05/38926994/zoom-q1-earnings-revenue-beat-eps-beat-cash-flow-surges-continued-ai-integration-and-more">매출과 이익 예상치를 뛰어넘는 강력한 1분기 실적을 발표한 </a>이후의 결정이다.
다른 중요한 거래들:
<ul>
<li>아크 인베스트는 마크포지드 홀딩(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MKFG#NYSE">MKFG</a>)의 주식 21,260주를 ARK Autonomous Technology &amp; Robotics ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKQ#BATS">ARKQ</a>)를 통해 매수했다. 아크 인베스트는 ARK Space Exploration &amp; Innovation ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#BATS">ARKX</a>)를 통해 마크포지드 8,776주를 구매했다.</li>
<li>아크 인베스트는 페이저듀티(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PD#NYSE">PD</a>)의 주식 15,383주를 ARK Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)를 통해 구매했다. 아크 인베스트는 ARK Genomic Revolution ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>)를 통해 아크투러스 테라퓨틱스 홀딩스(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/arct" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for ARCT">ARCT</a>)주식 39,589주를 매수했다.</li>
<li>아크 인베스트는 ARKW ETF를 통해 텔레닥 헬스 주식 229,654주를 매도했다. 아크 인베스트는 ARKK ETF를 통해 버브 테라퓨틱스 주식 125,257주를 매도했다. 이 회사는 ARKG ETF를 통해 버브 테라퓨틱스 주식 24,866주를 매도했다.</li>
</ul>
본 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>를 통해 제작되었으며, <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>이 수정했습니다.

ARCT

ARKG

ARKX

HOOD

MKFG

아크 인베스트는 로빈후드 주식 150만 달러를 매도하며, 줌 주식 330만 달러 상당도 처분

월요일에 캐시 우드가 주도하는 아크 인베스트(Ark Invest)는 로빈후드 마켓(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>)의 지분을 줄이는 중요한 조치를 취했다. 이 결정은 시장 변동 기간 중에 이루어졌으며 이 투자 회사가 자체 포트폴리오를 조정하는 최근 추세를 따랐다.
로빈후드(HOOD) 매매:
로빈후드에서 포지션을 축소하기로 한 아크 인베스트의 결정은 세 가지 ETF를 통해 실행되었다. ARK Fintech Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#NYSE">ARKF</a>)는 31,827주를 매각했고, ARK Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)와 ARK Next Generation Internet ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>)는 각각 215,675주와 76,299주를 매각했다. 월요일 로빈후드의 종가 23.42달러를 기준으로 판매된 주식의 총 가치는 약 760만 달러이다.
로빈후드 주식의 변동성은 <a href="https://www.benzinga.com/news/24/06/39234943/whats-going-on-with-robinhood-stock" target="_blank" rel="noopener">밈 주식 열기가 부활</a>하는 가운데 발생했다. 최근 로빈후드의 CEO 블래디미어 테네브는 게임스탑에 투자한 것으로 유명한 로어링 키티(Roaring Kitty)이라고도 알려진 키스 길(Keith Gill)의 예정된 라이브 스트리밍으로 인한 트래픽 유입을 회사가 처리할 준비가 되었다고 발표했다. 이 회사는 또한 최근 <a href="https://www.benzinga.com/news/24/05/39047461/robinhood-markets-stock-jumps-on-1b-buyback-whats-going-on">10억 달러 규모의 자사주 매입</a>을 발표했는데, 이는 주가 상승 추세에 기여했다.
특히 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)과 이더리움(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) 등 주요 코인들이 적자로 거래되면서 <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39262872/bitcoin-ethereum-dogecoin-remain-choppy-analyst-forecasts-2x-10x-increase-for-king-crypto-" target="_blank" rel="noopener">고르지 못한 암호화폐 시장</a>을 배경으로 거래가 성사됐다.
다른 중요한 거래:
<ul>
<li>이그젝트 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>): ARKG 및 ARKK를 통해 주식 매도.</li>
<li>아크투러스 테라퓨틱스 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>): ARKG를 통해 주식 매입.</li>
<li>텔라닥 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>): ARKG를 통해 주식 매도.</li>
<li>인텔리아 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>): ARKG 및 ARKK를 통해 주식 매입.</li>
<li>버브 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>): ARKG 및 ARKK를 통해 주식 매도. 베라사이트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>): ARKG 및 ARKK를 통해 5,804주 매입.</li>
</ul>
다음 읽어보기: <a href="https://www.benzinga.com/markets/equities/24/06/39246807/investor-naval-ravikant-threatens-to-sell-all-tesla-holdings-if-ceo-musks-pay-plan-is-rejected-b?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">CEO 일자리 대안에 대한 투자자의 협상</a>
이 이야기는 <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>의 편집을 거쳐 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>에 의해 제작되었습니다.

EXAS

아크 인베스트가 게임스톱 관련 뉴스와 비트코인 변동성 속에서 로빈후드 주식 $7.6백만 매각

Comments

Teladoc Health

뉴스

에 대한 최신 뉴스 Teladoc Health (NYSE:TDOC) 주식

목요일, 10월 31, 2024

목요일, 8월 01, 2024

수요일, 7월 31, 2024

목요일, 7월 04, 2024

화요일, 7월 02, 2024

목요일, 6월 27, 2024

화요일, 6월 25, 2024

목요일, 6월 13, 2024

화요일, 6월 11, 2024

화요일, 4월 16, 2024

금요일, 4월 12, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌